title: Adenosine receptor antagonists effect on plasma-enhanced killing.
abstract: Previous studies demonstrated that naive plasma has inherent capabilities to enhance bacterial opsonization and phagocyte killing, but not all plasma is equally effective. This raised the question of whether plasma constituents other than opsonins may play a role. Adenosine receptor antagonists have been shown to modulate cytokine response and survival in mice after a bacterial challenge. We investigated whether selective adenosine receptor blockade would influence the ability of naive plasma to effectively control bacterial growth. Colonic bacteria- and thioglycollate-elicited peritoneal macrophages and neutrophils were obtained from naive mice. Stock murine plasma from naive was purchased and categorized as having high plasma-enhanced bacterial killing capacity using our previously described methods. Bacteria and plasma were incubated to allow for opsonization and then added to macrophages previously exposed to selected adenosine receptor antagonists: ZM 241385: A2A, MRS1754: A2B, DPCPX: A1, and MRS1220: A3. The final mixture was plated on blood agar plates in aerobic and anaerobic conditions and bacterial colony-forming units quantified after 24 h. This study demonstrated that exogenous adenosine was able to significantly decrease phagocyte killing of cecal bacteria. Blocking adenosine receptors with selective antagonists altered the bacterial killing capacity of plasma. Selectively blocking the A1, A2A, or A2B receptors proved most beneficial at reversing the effect of adenosine. Consistent with previous work, only macrophage killing of bacteria could be modulated by adenosine receptor blockade because neutrophils were unaffected. These data demonstrate that adenosine decreases macrophage killing of enteric bacteria and that this effect is mediated through the adenosine receptors.
authors.affiliation: Departments of *Surgery and †Pathology and Laboratory Medicine, Boston University School of Medicine and Boston Medical Center, Boston, Massachusetts.
authors.forename: Gustavo
authors.initials: G
authors.lastname: Bauzá
authors.forename: Rituparna
authors.initials: R
authors.lastname: Moitra
authors.forename: Daniel
authors.initials: D
authors.lastname: Remick
mesh_terms: D000241:Adenosine / Q000276:immunology / Q000494:pharmacology; D000818:Animals; D001770:Blood Bactericidal Activity / Q000187:drug effects*; D002478:Cells, Cultured; D003106:Colon / Q000382:microbiology; D015169:Colony Count, Microbial; D005260:Female; D017737:Macrophages, Peritoneal / Q000187:drug effects / Q000502:physiology; D051379:Mice; D008813:Mice, Inbred ICR; D010533:Peritoneal Lavage; D010587:Phagocytosis / Q000187:drug effects; D010949:Plasma; D058915:Purinergic P1 Receptor Antagonists / Q000494:pharmacology*; D018805:Sepsis / Q000276:immunology; D015610:Serum Bactericidal Test / Q000379:methods
chemical_list: D058915:Purinergic P1 Receptor Antagonists; D000241:Adenosine